Candesartan in Heart Failure—Alternative Trial - CHARM Alternative Trial

Description:

The goal of the CHARM Alternative Trial was to assess the effect of the long-acting angiotensin II type 1 receptor blocker, candesartan cilexetil, in patients with symptomatic heart failure (HF), left ventricular ejection fraction (LVEF) ≤40%, and angiotensin-converting enzyme (ACE) inhibitor intolerance.